Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
- PMID: 34716096
- PMCID: PMC8542444
- DOI: 10.1016/j.smim.2021.101507
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Abstract
Coronaviruses are evolutionarily successful RNA viruses, common to multiple avian, amphibian and mammalian hosts. Despite their ubiquity and potential impact, knowledge of host immunity to coronaviruses remains incomplete, partly owing to the lack of overt pathogenicity of endemic human coronaviruses (HCoVs), which typically cause common colds. However, the need for deeper understanding became pressing with the zoonotic introduction of three novel coronaviruses in the past two decades, causing severe acute respiratory syndromes in humans, and the unfolding pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This renewed interest not only triggered the discovery of two of the four HCoVs, but also uncovered substantial cellular and humoral cross-reactivity with shared or related coronaviral antigens. Here, we review the evidence for cross-reactive B cell memory elicited by HCoVs and its potential impact on the puzzlingly variable outcome of SARS-CoV-2 infection. The available data indicate targeting of highly conserved regions primarily in the S2 subunits of the spike glycoproteins of HCoVs and SARS-CoV-2 by cross-reactive B cells and antibodies. Rare monoclonal antibodies reactive with conserved S2 epitopes and with potent virus neutralising activity have been cloned, underscoring the potential functional relevance of cross-reactivity. We discuss B cell and antibody cross-reactivity in the broader context of heterologous humoral immunity to coronaviruses, as well as the limits of protective immune memory against homologous re-infection. Given the bidirectional nature of cross-reactivity, the unprecedented current vaccination campaign against SARS-CoV-2 is expected to impact HCoVs, as well as future zoonotic coronaviruses attempting to cross the species barrier. However, emerging SARS-CoV-2 variants with resistance to neutralisation by vaccine-induced antibodies highlight a need for targeting more constrained, less mutable parts of the spike. The delineation of such cross-reactive areas, which humoral immunity can be trained to attack, may offer the key to permanently shifting the balance of our interaction with current and future coronaviruses in our favour.
Keywords: Antibodies; Coronavirus disease 2019 (COVID-19); Heterologous immunity; Heterotypic immunity; Human coronaviruses; Humoral immunity; Immunological memory; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Copyright © 2021. Published by Elsevier Ltd.
Conflict of interest statement
The authors report no declarations of interest.
Figures

Similar articles
-
Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.Front Immunol. 2021 Jul 27;12:696370. doi: 10.3389/fimmu.2021.696370. eCollection 2021. Front Immunol. 2021. PMID: 34386006 Free PMC article.
-
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.mBio. 2024 Feb 14;15(2):e0272223. doi: 10.1128/mbio.02722-23. Epub 2024 Jan 25. mBio. 2024. PMID: 38270455 Free PMC article.
-
Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.JAMA Netw Open. 2023 Jun 1;6(6):e2319222. doi: 10.1001/jamanetworkopen.2023.19222. JAMA Netw Open. 2023. PMID: 37389876 Free PMC article.
-
Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study.Microorganisms. 2021 Jul 31;9(8):1643. doi: 10.3390/microorganisms9081643. Microorganisms. 2021. PMID: 34442723 Free PMC article. Review.
-
The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.J Gen Virol. 2020 Aug;101(8):791-797. doi: 10.1099/jgv.0.001439. J Gen Virol. 2020. PMID: 32430094 Free PMC article. Review.
Cited by
-
The SARS-COV-2 Seroprevalence among Oncology Patients.J Clin Med. 2023 Jan 9;12(2):529. doi: 10.3390/jcm12020529. J Clin Med. 2023. PMID: 36675457 Free PMC article.
-
Neutralizing immunity against coronaviruses in Tanzanian health care workers.Sci Rep. 2024 Mar 6;14(1):5508. doi: 10.1038/s41598-024-55989-4. Sci Rep. 2024. PMID: 38448564 Free PMC article.
-
Editorial: Cross-reactive immunity and COVID-19.Front Immunol. 2024 Dec 9;15:1509379. doi: 10.3389/fimmu.2024.1509379. eCollection 2024. Front Immunol. 2024. PMID: 39717772 Free PMC article. No abstract available.
-
Persistently positive SARS-CoV-2-specific IgM during 1-year follow-up.J Med Virol. 2022 Sep;94(9):4037-4039. doi: 10.1002/jmv.27822. Epub 2022 May 12. J Med Virol. 2022. PMID: 35505640 Free PMC article. No abstract available.
-
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.BMC Med. 2022 Mar 3;20(1):102. doi: 10.1186/s12916-022-02312-5. BMC Med. 2022. PMID: 35236358 Free PMC article.
References
-
- Cohn M. The common sense of the self-nonself discrimination. Springer Semin. Immunopathol. 2005;27(1):3–17. - PubMed
-
- Davis M.M., Bjorkman P.J. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334(6181):395–402. - PubMed
-
- Klinman N.R. The "clonal selection hypothesis" and current concepts of B cell tolerance. Immunity. 1996;5(3):189–195. - PubMed
-
- Stockinger B., Kassiotis G., Bourgeois C. CD4 T-cell memory. Semin. Immunol. 2004;16(5):295–303. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous